Aims/hypothesis An increasing amount of evidence indicates that mannose-binding lectin (MBL) plays a role in the development of diabetic nephropathy. The main objective of the study was to analyse whether MBL influences the effects of diabetes on the kidneys. Materials and methods In one group of wild-type mice and in one group of MBL double knockout mice we induced diabetes by the use of streptozotocin as a model of type 1 diabetes. Two groups of non-diabetic mice, wild-type and MBL knockout, were also included. By two-way ANOVA we evaluated if MBL modulated the effects of diabetes by testing the interaction between diabetes and MBL. Results MBL interacted with the effects of diabetes on three outcome measures: kidney weight (p<0.001), urinary albumin excretion (p=0.001) and the expression of collagen IVα1 (Col4a1) mRNA (p=0.002). This means that the effects that diabetes normally has on these parameters were significantly modified by MBL. MBL showed a tendency to interact with the effects of diabetes on glomerular basement membrane thickness and total mesangial volume (p=0.065 and p=0.063, respectively). Glomerular volume and total mesangial volume were significantly smaller in animals lacking MBL than in wild-type animals (p=0.006 and p=0.047, respectively). Conclusions/interpretation These findings, for the first time, show that the degree of kidney alteration as a consequence of diabetes is modified by MBL. These findings support a pivotal role of MBL in the development of diabetic kidney disease.
. Despite the existing intervention strategies, diabetes is still a major single cause of end-stage renal failure. Accordingly, there is an ongoing need for the development of new additional intervention strategies. Recent reports indicate an involvement of mannose-binding lectin (MBL) from the complement system in the pathogenesis of diabetic kidney disease [3] . Under normal conditions MBL does not bind to the body's own structures, but it does possess potential self-reactive properties. A significant association between serum MBL levels and renal function has been reported in normoalbuminuric, microalbuminuric and macroalbuminuric type 1 diabetic patients [4] [5] [6] . Furthermore, in a cohort study of type 1 diabetic patients followed for 18 years from diagnosis, serum MBL was a significant predictor of later renal impairment. In patients with MBL levels above the median, 41% developed micro-or macroalbuminuria, in contrast to 26% of patients with levels below the median [7] . To evaluate a potential specific effect of MBL on the pathogenesis of diabetic kidney disease, we induced type 1 diabetes in wild-type and genetically modified MBL double knockout mice and examined the functional and structural renal changes. The data were evaluated for interaction between diabetes and MBL, effect of MBL and effect of diabetes.
Materials and methods
Animals and protocols We used adult, 11-week-old, female double MBL knockout, i.e. lacking both murine forms of MBL (MBL A and MBL C), C57BL/6J background (own breeding, backcrossed six generations for >95% C57BL/6J genetic background) [8] , and age-matched, female wildtype mice, C57BL/6J background (Taconic, Ry, Denmark). We used only female mice as they reach the adult bodyweight (BW) plateau faster than male mice. The animals had an initial BW of 17-23 g and were housed six to eight per cage in a room with a 12 h light-dark cycle (light on 07.00-19.00 h), a temperature of 21±1°C and humidity of 55±5%. Animals had free access to autoclaved standard chow (Altromin #1324; Lage, Germany) and autoclaved tap water. Diabetes was induced in wild-type and MBL knockout mice by five i.p. injections of streptozotocin (STZ) (Upjohn, Kalamazoo, MI, USA) on five consecutive days (doses of 45 mg/kg BW). The animals were re-injected with doses of 45 mg STZ/kg BW i.p. until diabetes was achieved. When mean blood glucose reached ≥16 mmol/l in the two diabetic groups we started the experimental period. Only animals without ketonuria or signs of illness (i.e. fast weight losses) were included. Principles of laboratory animal care (NIH publication no. 85-23, revised 1985) were followed and the study complied with the Danish regulations for care and use of laboratory animals.
The mice were randomised into four groups: (1) nondiabetic wild-type animals (ND-WT, n=7); (2) non-diabetic MBL knockout animals (ND-KO, n=8); (3) diabetic wildtype animals (D-WT, n = 11); and (4) diabetic MBL knockout (D-KO, n=11). BW and blood glucose were measured regularly throughout the study. Food consumption was determined at the beginning and end of the study. Eight weeks after induction of diabetes the mice were placed in metabolism cages to collect 24 h urine samples for determination of urinary albumin excretion (UAE). The animals were killed under anaesthesia by ketamine (Ketaminol Vet; Intervet, Skovlunde, Denmark) and xylazine (Narcoxyl Vet; Intervet) using a dose of 100 mg/kg BW ketamine and 10 mg/kg BW xylazine i.p. and non-fasting blood samples were drawn by heparinised capillary tubes from the retroorbital venous plexus. Blood samples were stored at −80°C until analysis was performed. The kidneys, livers and hearts were dissected and weighed. The kidney poles were snap frozen in liquid nitrogen for later determination of mRNA expression by real-time PCR (RT-PCR). The middle piece of the left kidney (including the papilla) was fixed in 4% paraformaldehyde for determination of glomerular volume by light microscopy (LM). The middle piece of the right kidney (including the papilla) was fixed in 0.1 mol/l cacodylate buffer with 2.5% glutaraldehyde and 2% paraformaldehyde for determination of glomerular basement membrane thickness (BMT) and mesangial fraction by electron microscopy.
Determination of blood glucose and urine analysis Blood glucose was measured weekly in tail-capillary blood by Precision Xtra Plus (Abbott Laboratories, MediSence Products, Bedford, MA, USA). Urine was tested for glucose and ketone bodies by a Combur 5 Test D (Roche Diagnostics GmbH, Mannheim, Germany).
Determination of UAE and urinary creatinine concentration Urine samples were stored at −20°C until the assay was performed. UAE was determined in 24 h urine collections by a commercially available kit, the Mouse Albumin ELISA Quantification Kit (Bethyl Labatories, Inc., Montgomery, TX, USA) according to the manufacturer's instructions. Urinary creatinine concentration was measured by an automated technique adapted from the method of Jaffé and corrected for the prevailing glucose content due to interference in the Jaffé reaction [9, 10] . The intra-and inter-assay CVs were <5 and <10%, respectively, for both assays.
Estimation of glomerular volume The paraformaldehydefixed middle part of the left kidney (containing the papilla) was embedded in paraffin for LM examination. Twomicron thick sections were cut on a rotation microtome and stained with haematoxylin and eosin. The mean glomerular tuft volume (V G ) was determined from measurements of the mean glomerular cross-sectional area (A G ) at a magnification of ×345 as previously described [11] . Crosssectional area were determined with a two-dimensional version of the nucleator (CAST, Olympus, Denmark) by LM as the average area of a total of 40-80 glomerular profiles (tuft omitting the proximal tubular tissue within the Bowmann capsule). V G was calculated as: V G =β/k×(A G ) 1.5 , where β=1.38, which is the shape coefficient for spheres (the idealised shape of glomeruli), and k=1.1, which is a size distribution coefficient.
Estimation of BMT, mesangial fraction and total mesangial volume The middle part of the right kidney (containing the papilla) was embedded in Epon 825 for electron microscopy examination. Thin sections were cut on a Reichert Ultracut (Leica, Austria) and stained with uranyl acetate and lead citrate. From an electron microscope (CM10, Phillips, Holland), images covering the whole glomerular profile were recorded with a MegaView video camera (Soft Imaging System, Münster, Germany) applying a multiple image alignment system onto a monitor. On the individual images the fraction of mesangium was measured applying a point count technique with a final magnification of ×9,200. BMT was measured in randomised fields at a final magnification of ×62,000 from the same sections described above. BMT was measured applying the orthogonal intercept method as previously described [12] . About 60 measurements were performed per glomerulus and BMT is given as a harmonic mean.
Quantitative RT-PCR After homogenisation of kidney pole tissue by the use of an MM301 Mixer Mill (Retsch, Haan, Germany), total cellular RNA was extracted from renal cortical tissue using a 6100 Nucleic Acid PrepStation (Applied Biosystems, Foster City, CA, USA). The quality of rRNA was estimated by agarose gel electrophoresis by the appearance of two distinct bands visible by fluorescence of ethidium bromide representing intact rRNA. The amounts of RNA extracted were quantified by measuring the absorbance at 260 nm by spectrophotometry. Reverse transcription from RNA to DNA was performed with a Multiscribe Reverse Transcriptase kit from Applied Biosystems under the following conditions: 25°C for 10 min, 48°C for 30 min and 94°C for 29 s. The PCR was performed in triplicates of each sample in a volume of 25 μl in each well containing RNA, TaqMan Universal PCR MasterMix and primers amplifying TGF-β (Tgfb, also known as Tgfb1) (Mm 00441724), connective tissue growth factor (Ctgf) (Mm 00515790), Col4a1 (185088267A), fibronectin (Fn1) (1546736), vascular endothelial growth factor A (Vegf-A, also known as Vegfa) (Mm 00437304), vascular endothelial growth factor receptor 2 (Vegfr-2, also known as Kdr) (Mm 00440099), nephrin (Nphs1) (Mm 497828) and the housekeeping gene, 18S (4319413) purchased from Applied Biosystems. Liver RNA was used as negative controls. Each RT-PCR reaction ran at 50°C for 2 min, at 95°C for 10 min and in 40 cycles changing between 95°C for 15 s and 60°for 1.30 min.
PCR data analysis Data were analysed with the ABI Prism 7000 Sequence Detector Software from Applied Biosystems. The output of amplification was measured in the exponential phase of the reaction as the threshold cycle/Ctvalue, which is defined as the cycle number at which amplification products are detected, corresponding to the point where fluorescent intensity exceeds the background fluorescent intensity, which is 10×SD of the baseline. The average of triplicates from each sample was used. The relative quantification of target gene was calculated by the formula (½) Ct-target gene-Ct-housekeeping gene , which is described in the Users Bulletin 2, 1997, from Perkin-Elmer (Perkin-Elmer Cetus, Norwalk, CT, USA) [13] .
Statistical analysis
The study was a 2×2 factorial experiment. The four groups of animals were generated from two factors: one factor was diabetes (yes/no) and the other factor was MBL status (wild-type/MBL knockout). By two-way ANOVA models the questions of interest were evaluated. The main question of interest was addressed first: the interaction of diabetes and MBL status (D×MBL), i.e. is the effect of diabetes on the various outcome measures different in the presence of MBL (i.e. in the wild-type animals) than in the absence of MBL (i.e. in the MBL knockout animals)? When variables showed interaction between diabetes and MBL (D×MBL) we tested the hypothesis: No difference between the two non-diabetic groups, i.e. no effect of MBL in non-diabetic mice. When variables showed no interaction between diabetes and MBL (D×MBL) the effects of MBL (wild-type vs MBL knockout) are independent of diabetes (no diabetes vs diabetes) and the effects of diabetes (no diabetes vs diabetes) are independent of MBL (wild-type vs MBL knockout). Thus we tested the hypothesis: No overall effect of MBL status. If no effect of MBL we tested the hypothesis: No effect of diabetes. If MBL did influence the outcome no further tests were performed.
The ANOVA models were fitted after consideration of appropriated transformations of the data to achieve near-normality and equal variances. After these considerations one-way tests were performed to test if the groups differed overall or not. We only tested the hypotheses mentioned above if the mean of the variable differed significantly between the four groups. For data that could not be transformed to achieve near-normality the Mann-Whitney rank sum test was used. All data from the RT-PCR measurements were transformed by the natural logarithm to give comparisons as ratios rather than differences. Liver weight could not be transformed to achieve near-normality. Measurements by electron microscopy and RT-PCR were made on selected animals of each group (see Table 1 ). This reduction in numbers was made due to technical limitations. All selections were random.
All data are expressed as means±SEM, with n indicating the number of mice studied (number as stated in the Animals and protocols section except when other numbers are given) or mean and 95% CIs. p values <0.05 are considered as significant. p values <0.10 and >0.05 are considered tendency. Statistical analysis was performed using the statistical package STATA for Microsoft Windows.
Results BW, blood glucose and food consumption At the start and end of the study the mean BW did not differ significantly between the four groups (data not shown). Food consumption, which was measured at group basis, did not differ between the four groups at the start of the study. By the end of the study diabetic animals had increased food consumption when compared with non-diabetic animals. No difference in food consumption was observed, either between the non-diabetic groups or between the diabetic groups (data not shown). The average levels of blood glucose in the diabetic groups during the study period were 16.1 ± 0.4 mmol/l (D-WT) and 16.1±0.5 mmol/l (D-KO). The average blood glucose levels in the non-diabetic groups were 7.2±0.3 mmol/l (ND-WT) and 6.6±0.3 mmol/l (ND-KO). The blood glucose level did not differ between the two diabetic groups or the two non-diabetic groups.
Kidney weight, glomerular volume and UAE The effect of diabetes on kidney weight (Table 1 and Fig. 1 ) was Fig. 1) showed an interaction between diabetes and MBL (p = 0.001). Second, we found a significant difference between the non-diabetic groups, as UAE in the non-diabetic MBL knockout animals was increased 2.72-fold (95% CI 1.66-4.45) compared with the non-diabetic wild-type animals (p<0.001).
BMT, total mesangial volume and mesangial fraction BMT (Table 1 and Fig. 2) showed a tendency to interaction between diabetes and MBL, although this did not reach significance (p=0.065). MBL did not influence BMT (p= 0.142) and the effect of diabetes alone did not reach statistical significance (p=0.051), but only tended to.
A tendency to interaction (D×MBL) was found on the total mesangial volume (p=0.063), but this did not reach statistical significance (Table 1 and Fig. 2 ). MBL did significantly influence this measure as the MBL knockout animals had an 8,788 μm 3 (95% CI 120-17,456) smaller mesangium than wild-type animals (p=0.047).
The mesangial fraction was not subject to D×MBL interaction (p =0.220) or effects of MBL (p =0.311). Diabetic animals had a 6.4% (95% CI 2.7-10.0) larger mesangial fraction than non-diabetic animals (p=0.002).
Renal gene transcription Diabetes and MBL did not show interaction on the outcomes Tgfb and Ctgf (Table 1 and Fig. 3 ). Likewise we found no significant effect of MBL. The expressions of both Tgfb and Ctgf mRNA were increased in the diabetic animals compared with the non- Table 1 for back-transformed geometric means and back-transformed 95% CIs). See "Materials and methods" section and Table 1 Fig. 3) showed interaction between diabetes and MBL (p= 0.002). Thus, we compared the two non-diabetic groups. The non-diabetic MBL knockout animals had a 1.29-fold (95% CI 1.07-1.56) higher Col4a1 expression compared with non-diabetic wild-type animals (p=0.011). Fn1 expression showed no interaction between diabetes and MBL (p=0.232) and no effect of MBL (p=0.092). However, diabetes did significantly influence the outcome, as the expression was 3.80-fold (95% CI 2.90-4.99) increased in the diabetic animals (p<0.001).
Vegf-A expression was not subject to D×MBL interaction (p=0.542). MBL alone had no significant effect on this outcome (p=0.169). The Vegf-A expression in diabetic animals was decreased to 77% of the non-diabetic level (95% CI 69.2-85.1, p<0.001). We found no difference in mean Vegfr-2 or Nphs1 mRNA expressions (data not shown).
Heart and liver weight We found no interaction (D×MBL) on heart weight (p=0.481) and no effect of MBL (p=0.711) ( Table 1) . Looking at diabetes alone we found that diabetic animals had a significantly decreased heart weight that was 8.4 mg (95% CI 3.8-13.0) lower than in non-diabetic animals (p=0.001). The liver weights in the four groups were tested by non-parametric tests as data could not be transformed to achieve near-normality. Both diabetic groups showed significantly increased liver weight (median [25% percentile- 
Discussion
The major new findings of the present study are that MBL deficiency attenuates several of the classic functional and physical renal changes seen in an experimental model of type 1 diabetes.
The main target of this study was to investigate if MBL had any influence on the alterations normally seen in the kidneys Statistical analyses were performed on log-transformed data and bars thus indicate geometric means (see Table 1 for back-transformed geometric means and back-transformed 95% CIs). See Materials and methods section and Table 1 for further details in the mouse model of type 1 diabetes we used. By two-way ANOVA analyses we found this to be the case concerning kidney weight, UAE and Col4a1 mRNA expression. MBL tended to modify the effects of diabetes on BMT and total mesangial volume. Furthermore, we observed marked effects of MBL on both glomerular volume and total mesangial volume as these were smaller in animals lacking MBL. All renal effects of MBL deficiency were observed without effects on blood glucose, BW or food consumption, thus indicating a specific role of MBL in the pathogenesis of diabetes-induced renal changes.
MBL initiates the complement system via the MBL pathway by its binding to repetitive carbohydrate structures found on microorganisms [3, 14] . This interaction activates the MBL-associated serine proteases, which then cleave C4 and C2. This results in generation of C3 convertase, which initiates the rest of the complement cascade, and generation of the membrane-attack complex (MAC) on the surface of the pathogen. This can cause its lysis. The complement activation also generates fragments that are opsonic, chemotactic and, as recently discovered, bactericidal [15] .
The serum level of MBL varies considerable (1,000-fold) in the Europid population and the individual level is mainly genetically determined with relatively small fluctuations [16] . The median level of MBL in serum is 800-1,000 μg/l, but in one-third of the population the level is <500 μg/l and in about one-tenth even lower than 100 μg/l [17, 18] .
In clinical trials, normoalbuminuric patients with type 1 diabetes have higher serum MBL levels than non-diabetic controls [4, 5] . The groups had the same distribution of MBL genotypes [5] . In these studies, MBL levels correlated with UAE within the normal range, but not with metabolic control. The serum MBL levels were increased in microalbuminuric type 1 diabetic patients when compared with normoalbuminuric patients [6] . Diabetic nephropathy was more prevalent among type 1 diabetic patients with a high MBL expression genotype and high circulating MBL levels than among patients with a low MBL genotype and low serum MBL levels [5] . In a recent study in type 1 diabetic patients, followed for 18 years from diagnosis, high MBL level at baseline was a significant predictor of the development of either microalbuminuria or overt nephropathy [7] .
In support of these indirect clinical data indicating an importance of MBL levels in diabetic nephropathy, the present study provides direct evidence for an involvement of MBL in the pathogenesis of diabetic kidney disease. Interaction of MBL and diabetes regarding kidney weight, Col4A1 mRNA expression and albumin excretion demonstrate attenuated renal effects of diabetes in a completely MBL-deficient state.
The crucial role of various growth factors and cytokines in the pathogenesis of diabetic kidney disease has recently been reviewed [19] . Tgfb has been shown to be involved in the pathogenesis of diabetic kidney disease in different animal models [20] [21] [22] . Furthermore, it has been suggested that CTGF plays a role in diabetic kidney disease partly modulated by TGF-β signalling [23] [24] [25] . TGF-β and CTGF are thought to induce renal fibrosis in part through an upregulation of Col4a1 and Fn1 expression [23, 24] . In the present study we observed interaction between diabetes and MBL on Col4a1 expression. This means that the effect of diabetes on Col4a1 expression is strongly modified by MBL. Tgfb, Ctgf and Fn1 did not show any interaction or isolated effect of MBL status. The expression of these three genes was only affected by diabetes, causing an increase in expression.
VEGF-A is produced in the podocytes and has been shown to be upregulated in different animal models of diabetes, e.g. in the STZ-diabetic rat [26] [27] [28] [29] [30] . In these studies the most pronounced upregulation was observed in the early stages of the disease. In vitro experiments have demonstrated an increased proliferation and collagen production in mesangial cells in response to VEGF exposure [31, 32] . Vegfr-2 has been shown to be upregulated in the early stage of diabetes, but not in long-term diabetes [27] . Deterioration of the slit diaphragm is associated with decreased glomerular filter integrity [33] . The existence and function of this diaphragm is critically dependent on nephrin and decreased production of this protein has been observed in different types of kidney disease [34, 35] . Decreased Fn1 expression has been observed in long-term diabetes, but not in the early stage of the disease [36] .
In the present study we observed no diabetes×MBL interaction on Vegf-A expression or any separate effect of MBL. Diabetic animals had significantly lower Vegf-A expression than the non-diabetic animals. This is consistent with another study from our group on STZ-diabetic mice killed after 60 days with diabetes [37] . Expression of Vegfr-2 and Nphs1 did not differ between the four groups in the present study. The time-point for the determination of mRNA expression might explain the disagreement of our observations with prior reports concerning VEGF-A. The equal expression of Vegfr-2 in the four groups in the present study is in agreement with previous results that demonstrated an enhanced expression of the receptor only in the early course of diabetes [27] . Likewise the lack of difference in Nphs1 expression may be explained by the determination of mRNA levels earlier than in previously reports [36] .
In patients with diabetes the complement system could potentially be activated through different mechanisms. An inactivation of the complement regulatory proteins by glycation has been postulated. Under normal conditions complement regulatory proteins, e.g. CD59, prevent formation of MACs on the self-tissue. The increased blood glucose in diabetic patients could induce glycation of complement regulatory proteins and by this mean inactivate the proteins [38] . Glycation of CD59 happens in vivo in humans, but not in C57 mice. This glycation attenuates its capacity to inhibit MAC formation [38] . It has been shown that MAC formation happens on cells and can lead to the release of growth factors without effects on cell viability [39] . Immunohistochemical studies observed no normal CD59 in the areas with severe glomerulosclerotic tissue and pronounced MAC deposition in diabetic patients [40] . In another study, deposition of glycated CD59 was observed in the kidneys and nerves of diabetic patients, but not in nondiabetic patients. In about 60% of the same samples MACs were found colocalised with glycated CD59 [41] . Erythrocytes from diabetic patients were more susceptible to MACmediated lysis compared with those from non-diabetic subjects due to inactivation of CD59 by glycation [41] .
In conclusion, intensive metabolic and antihypertensive management remain cornerstones in the treatment of diabetic patients with micro-or macrovascular complications. An emerging amount of evidence suggests that the complement system may offer a strategy of intervention against the progression or even development of vascular complications to diabetes. Multiple drugs for specific manipulation of the complement system, e.g. a soluble complement receptor 1, and a specific C5 inhibitor, are under clinical evaluation [42] [43] [44] . Whether or not these drugs will provide new treatments of diabetic complications is still unknown. MBL deficiency is known to be associated with an increased risk of a broad range of infections [45] [46] [47] and adverse effects of inhibition of the complement system might hinder manipulation on a long-term basis.
